The data in this article is related to the research article entitled "Notch2 signaling promotes osteoclast resorption via activation of PYK2" (Jin et al., 2016 [1]). To block Notch signaling activation, we used several gamma-secretase inhibitors (GSIs) and evaluate the inhibitory potential of GSIs on osteoclastogenesis. We measured the effect of GSIs on osteoclastogenesis and normal spreading of osteoclasts by using the mouse bone marrow-derived macrophages (BMMs) which may contributes to insight of physiological relevant of in vivo. This data article suggests valuable approach to GSIs treatment doses and potential of those in the osteoclast differentiation and spreading.
a b s t r a c t
The data in this article is related to the research article entitled "Notch2 signaling promotes osteoclast resorption via activation of PYK2" (Jin et al., 2016 [1] ). To block Notch signaling activation, we used several gamma-secretase inhibitors (GSIs) and evaluate the inhibitory potential of GSIs on osteoclastogenesis. We measured the effect of GSIs on osteoclastogenesis and normal spreading of osteoclasts by using the mouse bone marrow-derived macrophages (BMMs) which may contributes to insight of physiological relevant of in vivo. This data article suggests valuable approach to GSIs treatment doses and potential of those in the osteoclast differentiation and spreading. This data provides starting and target doses for several GSIs against osteoclast differentiation and spreading that offers valuable approach for investigation of Notch signaling and gamma-secretase involvement in osteoclast differentiation and cytoskeletal organization.
Data
This data provides supporting information of the role of Notch signaling on osteoclast differentiation and function [1] . Notch signaling has been shown to regulate osteoclastogenesis negatively by Notch1 or positively by Notch2 [2] . To investigate whether Notch signaling affects osteoclast differentiation and spreading, we assessed the inhibitory potential of four GSIs from BMM to mature osteoclast forming period.
Experimental design, materials and methods

Reagents
Recombinant human M-CSF and RANKL were purchased from PeproTech EC (London, UK). The gamma-secretase inhibitors, Dibenzazepin (PubChem CID: 11454028), L685,458 (PubChem CID: 5479543), Compound E (PubChem CID: 11306390) DAPT (PubChem CID:5311272) were purchased from Calbiochem-Merck Co (Darmstadt, Germany).
Cell culture
To obtain BMMs, bone marrow cells (BMCs) were collected by flushing tibiae from 5-week-old male ICR mice and red blood cells had been removed with ACK buffer (0.01 mM EDTA, 0.011 M KHCO 3 , and 0.155 M NH 4 CL, pH 7.3). Cells that had not attached to the culture dish were further cultured for three days in the presence of M-CSF (60 ng/ml) alone to generate BMM as previously described [3] .
To generate osteoclast, BMMs (4 Â 10 4 cells/well) were cultured in α-minimum essential medium (α-MEM) containing 10% (v/v) heat inactivated fetal bovine serum (FBS), 50 U/ml penicillin, and 50 μg/ml streptomycin on 48-well culture plates in the presence of M-CSF (60 ng/ml) and RANKL (100 ng/ml) for 4 days. The complete medium was changed every 3 days.
TRAP stain and measurement
Appeared osteoclasts were washed by PBS and fixed by 3.7% formalin for 20 min. Then, fixed cells were stained for tartrate-resistant acid phosphatase (TRAP) by using the Leukocyte Acid Phosphatase Assay kit (Sigma-Aldrich) following the manufacturer's procedure (Fig. 1A) . DMSO-or several GSIs- treated osteoclasts that contained three or more nuclei were counted by using of light microscope and the number of spreading osteoclasts was measured by using the OsteoMeasure XP program (version 1.01; OsteoMetrics) (Fig. 1B) .
Statistical analysis
All quantitative data are represented as means 7SDs (n Z3). Each experiment was performed 3-5 times, and the results from 1 representative experiment are shown. Statistical differences were analysed by Student's t-tests. A value of P o0.05 was considered statistically significant.
